BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Uche IK, Fowlkes N, Vu L, Watanabe T, Carossino M, Nabi R, Del Piero F, Rudd JS, Kousoulas KG, Rider PJF. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model. J Virol 2021;95:e01359-20. [PMID: 33177208 DOI: 10.1128/JVI.01359-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ziogas DC, Martinos A, Petsiou DP, Anastasopoulou A, Gogas H. Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers. Cancers (Basel) 2022;14:2873. [PMID: 35740539 DOI: 10.3390/cancers14122873] [Reference Citation Analysis]
2 Rider PJF, Kamil M, Yilmaz I, Atmaca HN, Kalkan-yazici M, Ziya Doymaz M, Kousoulas KG, Aly ASI. An Attenuated HSV-1-Derived Malaria Vaccine Expressing Liver-Stage Exported Proteins Induces Sterilizing Protection against Infectious Sporozoite Challenge. Vaccines 2022;10:300. [DOI: 10.3390/vaccines10020300] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Uche IK, Stanfield BA, Rudd JS, Kousoulas KG, Rider PJF. Utility of a Recombinant HSV-1 Vaccine Vector for Personalized Cancer Vaccines. Front Mol Biosci 2022;9:832393. [DOI: 10.3389/fmolb.2022.832393] [Reference Citation Analysis]
4 Uche IK, Kousoulas KG, Rider PJF. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment. Viruses 2021;13:1200. [PMID: 34206677 DOI: 10.3390/v13071200] [Cited by in F6Publishing: 3] [Reference Citation Analysis]